172@29@16@16!~!172@29@0@53!~!|commonstore|commonfiles|moneycontrol_header.php?cid=0&s_cid=0&radar_off=0&is_revamped_header=0&is_responsive=1&sec=PNC_ANNUALREPORT&priceinter=1&frommc=1!~!|commonstore|commonfiles|moneycontrol_header.php
Moneycontrol
SENSEX NIFTY
you are here:

Novartis India Ltd.

BSE: 500672 | NSE: NOVARTIND | Series: NA | ISIN: INE234A01025 | SECTOR: Pharmaceuticals

BSE Live

Aug 11, 10:23
640.60 2.85 (0.45%)
Volume
AVERAGE VOLUME
5-Day
31,909
10-Day
29,245
30-Day
20,147
2,825
  • Prev. Close

    637.75

  • Open Price

    638.20

  • Bid Price (Qty.)

    638.50 (31)

  • Offer Price (Qty.)

    640.75 (5)

NSE Live

Dec 27, 11:22
217.15 -1.70 (-0.78%)
Volume
No Data Available
6,787,243
  • Prev. Close

    218.85

  • Open Price

    -

  • Bid Price (Qty.)

    - (0)

  • Offer Price (Qty.)

    - (0)

Novartis India is not listed on NSE

Annual Report

For Year :
2018 2017 2016 2015 2014 2013 2012 2011 2010

Chairman's Speech

Dear Shareholder,

The history of our Company is closely linked to the history of India. We have completed 70 years of operating in the country in various business constructs and continue to be committed partners in India’s growth story. Through all of this, our commitment to the patient community remains unwavering.

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Our significant investment in research and development underpins our commitment to using science-based innovation to address some of society’s most challenging healthcare issues. Only by working together can we improve outcomes for patients and change the practice of medicine.

As a global company we are committed to implementing access strategies for all our new medicines based on three principles: addressing the needs of underserved populations through research and development; further improving affordability of our medicines; and strengthening healthcare systems. We are also committed to continuing to provide tailored and scalable access solutions, including patient assistance programs, equitable commercial models, social business models, zero-profit models and drug donations. We are committed to grow our business responsibly while always keeping patients at the centre of everything we do. In fact, we go beyond business through the various CSR initiatives we have, thus contributing to society.

Access to healthcare continues to be high on our agenda, together with meeting unmet medical needs of patients in India. We are extremely aware of our responsibility to provide affordable medicines, particularly to the rural poor. Under the umbrella of our social business Arogya Parivar, which completed 10 years since it started as a pilot in two districts, we have conducted close to 150,000 health education meetings in the previous financial year. During the same period, 398,618 people participated in 9,232 health camps held in 11 states. Arogya Parivar continues to evaluate newer models for healthcare delivery to underserved people, including leveraging digital technology to broaden reach.

In the following pages of this annual report, our newly appointed Vice Chairman & Managing Director Milan Paleja describes in some detail how our Company addresses access challenges in India. With his appointment the Board of Directors and I are confident that our Company is in good hands. He returns to India with rich multi-country experience which will be to the long-term benefit of the Company.

I thank you for continuing to place your trust and confidence in our Company and look forward to your continued support in the years ahead. On behalf of the Board of Directors, I am pleased to propose a dividend of ''10 per equity share of ''5 at the forthcoming Annual General Meeting.

Sincerely,

Christopher Snook Chairman